JP2016509047A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016509047A5 JP2016509047A5 JP2015558495A JP2015558495A JP2016509047A5 JP 2016509047 A5 JP2016509047 A5 JP 2016509047A5 JP 2015558495 A JP2015558495 A JP 2015558495A JP 2015558495 A JP2015558495 A JP 2015558495A JP 2016509047 A5 JP2016509047 A5 JP 2016509047A5
- Authority
- JP
- Japan
- Prior art keywords
- cycloalkyl
- alkyl
- heteroaryl
- aryl
- alkynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 225
- 125000000304 alkynyl group Chemical group 0.000 claims description 175
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 171
- 125000003342 alkenyl group Chemical group 0.000 claims description 162
- 125000001072 heteroaryl group Chemical group 0.000 claims description 145
- 125000000623 heterocyclic group Chemical group 0.000 claims description 145
- 125000003118 aryl group Chemical group 0.000 claims description 141
- 229910052799 carbon Inorganic materials 0.000 claims description 95
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 81
- 229910052739 hydrogen Inorganic materials 0.000 claims description 81
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims description 74
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 64
- 150000001875 compounds Chemical class 0.000 claims description 56
- 125000003545 alkoxy group Chemical group 0.000 claims description 45
- 125000004043 oxo group Chemical group O=* 0.000 claims description 42
- 229910052736 halogen Inorganic materials 0.000 claims description 36
- 150000002367 halogens Chemical class 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 35
- -1 heterocyclylene Chemical group 0.000 claims description 34
- 125000002947 alkylene group Chemical group 0.000 claims description 29
- 125000004104 aryloxy group Chemical group 0.000 claims description 27
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 27
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 27
- 239000000651 prodrug Substances 0.000 claims description 25
- 229940002612 prodrug Drugs 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 25
- 239000012453 solvate Substances 0.000 claims description 25
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 23
- 125000004419 alkynylene group Chemical group 0.000 claims description 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 20
- 125000004432 carbon atom Chemical group C* 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 18
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 18
- 125000004450 alkenylene group Chemical group 0.000 claims description 18
- 125000000732 arylene group Chemical group 0.000 claims description 18
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 18
- 125000005549 heteroarylene group Chemical group 0.000 claims description 18
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 18
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims description 18
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 17
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims description 17
- 125000004122 cyclic group Chemical group 0.000 claims description 16
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 14
- 125000003003 spiro group Chemical group 0.000 claims description 11
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 238000006467 substitution reaction Methods 0.000 claims description 9
- 230000001419 dependent effect Effects 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 229940072107 ascorbate Drugs 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 7
- 125000006586 (C3-C10) cycloalkylene group Chemical group 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 2
- 0 **N(*)Cc1nccc(*)c1 Chemical compound **N(*)Cc1nccc(*)c1 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361770058P | 2013-02-27 | 2013-02-27 | |
| US201361770065P | 2013-02-27 | 2013-02-27 | |
| US201361770067P | 2013-02-27 | 2013-02-27 | |
| US61/770,067 | 2013-02-27 | ||
| DKPA201370115 | 2013-02-27 | ||
| US61/770,058 | 2013-02-27 | ||
| DKPA201370113 | 2013-02-27 | ||
| DKPA201370113 | 2013-02-27 | ||
| DKPA201370114 | 2013-02-27 | ||
| DKPA201370114 | 2013-02-27 | ||
| DKPA201370115 | 2013-02-27 | ||
| US61/770,065 | 2013-02-27 | ||
| US201461931126P | 2014-01-24 | 2014-01-24 | |
| US61/931,126 | 2014-01-24 | ||
| PCT/EP2014/053674 WO2014131777A1 (en) | 2013-02-27 | 2014-02-26 | Inhibitors of histone demethylases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018082444A Division JP2018127486A (ja) | 2013-02-27 | 2018-04-23 | ヒストン脱メチル化酵素の阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016509047A JP2016509047A (ja) | 2016-03-24 |
| JP2016509047A5 true JP2016509047A5 (OSRAM) | 2017-03-30 |
| JP6514117B2 JP6514117B2 (ja) | 2019-05-15 |
Family
ID=51427545
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015558495A Active JP6514117B2 (ja) | 2013-02-27 | 2014-02-26 | ヒストン脱メチル化酵素の阻害剤 |
| JP2018082444A Withdrawn JP2018127486A (ja) | 2013-02-27 | 2018-04-23 | ヒストン脱メチル化酵素の阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018082444A Withdrawn JP2018127486A (ja) | 2013-02-27 | 2018-04-23 | ヒストン脱メチル化酵素の阻害剤 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9650339B2 (OSRAM) |
| EP (2) | EP3170811A1 (OSRAM) |
| JP (2) | JP6514117B2 (OSRAM) |
| KR (1) | KR102229992B1 (OSRAM) |
| CN (1) | CN105263906B (OSRAM) |
| AP (1) | AP2015008676A0 (OSRAM) |
| AU (2) | AU2014222756B2 (OSRAM) |
| BR (1) | BR112015020650A2 (OSRAM) |
| CA (1) | CA2901022C (OSRAM) |
| CL (1) | CL2015002394A1 (OSRAM) |
| CR (1) | CR20150507A (OSRAM) |
| EA (1) | EA030451B1 (OSRAM) |
| ES (1) | ES2670864T3 (OSRAM) |
| IL (1) | IL240439A0 (OSRAM) |
| MD (1) | MD20150085A2 (OSRAM) |
| MX (1) | MX2015011097A (OSRAM) |
| PE (1) | PE20151667A1 (OSRAM) |
| PH (1) | PH12015501868A1 (OSRAM) |
| PL (1) | PL2961736T3 (OSRAM) |
| SG (2) | SG11201506717UA (OSRAM) |
| SI (1) | SI2961736T1 (OSRAM) |
| TR (1) | TR201808599T4 (OSRAM) |
| WO (1) | WO2014131777A1 (OSRAM) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015003959A (es) | 2012-10-02 | 2015-11-16 | Epitherapeutics Aps | Inhibidores de histona demetilasas. |
| ES2670864T3 (es) | 2013-02-27 | 2018-06-01 | Gilead Sciences, Inc. | Inhibidores de histonas desmetilasas |
| AR099890A1 (es) * | 2014-03-31 | 2016-08-24 | Epitherapeutics Aps | Inhibidores de histona demetilasas |
| MX2017002451A (es) | 2014-08-27 | 2017-05-23 | Gilead Sciences Inc | Compuestos y metodos para inhibir histona desmetilasas. |
| MX2017005346A (es) | 2014-10-29 | 2017-08-02 | Dong A St Co Ltd | Nuevos compuestos de piridopirimidinona para modular la actividad catalitica de histona lisina desmetilasas (kdm). |
| AU2016250099A1 (en) * | 2015-04-14 | 2017-10-12 | Gilead Sciences, Inc. | Methods of treating hepatitis B virus |
| WO2017099829A1 (en) * | 2015-12-11 | 2017-06-15 | The General Hospital Corporation | Compositions and methods for treating drug-tolerant glioblastoma |
| EP3463469B1 (en) | 2016-05-27 | 2023-12-13 | Gilead Sciences, Inc. | Combination of ledipasvir and sofosbuvir for use in the treatment of hepatitis b virus infections in humans |
| BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| AU2017318601B2 (en) | 2016-09-02 | 2020-09-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| KR20230010826A (ko) | 2016-10-14 | 2023-01-19 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
| TW202510891A (zh) | 2017-01-31 | 2025-03-16 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
| JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| US20200155526A1 (en) * | 2017-05-31 | 2020-05-21 | The Children's Medical Center Corporation | Targeting lysine demethylases (kdms) as a therapeutic strategy for diffuse large b-cell lymphoma |
| AU2018328308A1 (en) | 2017-09-06 | 2020-04-16 | Translational Drug Development, Llc | Aminobenzimidazole derivatives, treatments, and methods of inhibiting histone deacetylase |
| US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| WO2019154261A1 (zh) * | 2018-02-09 | 2019-08-15 | 南京明德新药研发股份有限公司 | 与kmd5通路相关的吡啶衍生物 |
| JP7062792B2 (ja) | 2018-02-13 | 2022-05-06 | ギリアード サイエンシーズ， インコーポレイテッド | Ｐｄ－１／ｐｄ－ｌ１阻害剤 |
| CA3091142C (en) | 2018-02-26 | 2023-04-11 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| EP3781556B1 (en) | 2018-04-19 | 2025-06-18 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| CN118221646A (zh) | 2018-07-13 | 2024-06-21 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| JP2021534084A (ja) * | 2018-08-06 | 2021-12-09 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | ヒストンデメチラーゼ５阻害剤およびその使用 |
| KR102635333B1 (ko) | 2018-10-24 | 2024-02-15 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| MX2021005047A (es) | 2018-10-31 | 2021-09-08 | Gilead Sciences Inc | Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1. |
| CN117105933A (zh) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
| CN109852662B (zh) * | 2018-12-25 | 2021-02-19 | 华南农业大学 | 组蛋白甲基化H3K4me3在猪卵巢颗粒细胞中的应用 |
| US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| DK3934757T3 (da) | 2019-03-07 | 2023-04-17 | Inst Of Organic Chemistry And Biochemistry Ascr V V I | 2'3'-cykliske dinukleotider og prodrugs deraf |
| AU2020231115B2 (en) | 2019-03-07 | 2025-02-20 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| PE20220231A1 (es) | 2019-06-25 | 2022-02-07 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso |
| WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| EP4458975A3 (en) | 2019-09-30 | 2025-02-12 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
| EP4069729B1 (en) | 2019-12-06 | 2025-01-22 | Precision BioSciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| AR121620A1 (es) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos |
| US12110305B2 (en) | 2020-08-07 | 2024-10-08 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| AU2022274607A1 (en) | 2021-05-13 | 2023-11-16 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| JP7686086B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物 |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
| LU88769I2 (fr) | 1982-07-23 | 1996-11-05 | Zeneca Ltd | Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R)) |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| AU3732889A (en) * | 1988-11-11 | 1990-05-28 | Banyu Pharmaceutical Co., Ltd. | Substituted allylamine derivatives, process for their preparation and their use |
| JPH03173865A (ja) * | 1988-11-11 | 1991-07-29 | Banyu Pharmaceut Co Ltd | 置換アリルアミン誘導体、その製造法及びその用途 |
| US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
| US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
| NZ334821A (en) | 1996-08-30 | 2000-12-22 | Novartis Ag | Method for producing epothilones |
| DE69724269T2 (de) | 1996-09-06 | 2004-06-09 | Obducat Ab | Verfahren für das anisotrope ätzen von strukturen in leitende materialien |
| US5874438A (en) * | 1996-10-11 | 1999-02-23 | Bayer Aktiengesellschaft | 2,2'-bridged bis-2,4-diaminoquinazolines |
| US5756517A (en) * | 1996-10-25 | 1998-05-26 | Bayer Aktiengesellschaft | Use of bisquinoline compounds in the treatment of cerebral disorders |
| CN100344627C (zh) | 1996-11-18 | 2007-10-24 | 生物技术研究有限公司(Gbf) | 埃坡霉素c、其制备方法以及作为细胞抑制剂和植物保护剂的应用 |
| US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
| US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| ATE307123T1 (de) | 1998-02-25 | 2005-11-15 | Sloan Kettering Inst Cancer | Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen |
| EP1135470A2 (en) | 1998-11-20 | 2001-09-26 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| EA200400648A1 (ru) * | 2001-11-08 | 2005-04-28 | Элан Фармасьютикалз, Инк. | N, n'-замещенные производные 1,3-диамино-2-гидроксипропана |
| CA2478374C (en) | 2002-03-13 | 2009-01-06 | Eli M. Wallace | N3 alkylated benzimidazole derivatives as mek inhibitors |
| WO2006129842A1 (ja) * | 2005-06-01 | 2006-12-07 | Banyu Pharmaceutical Co., Ltd. | オーロラa選択的阻害作用を有する新規アミノピリジン誘導体 |
| WO2008002671A2 (en) | 2006-06-29 | 2008-01-03 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors |
| SA109300195B1 (ar) | 2008-03-28 | 2013-04-20 | Astrazeneca Ab | تركيبة صيدلانية جديدة مضادة للسرطان |
| MX2011004553A (es) | 2008-10-29 | 2011-07-20 | Sirtris Pharmaceuticals Inc | Piridina, piridina biciclica y analogos relacionados como moduladores de sirtuina. |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| WO2011017583A1 (en) | 2009-08-07 | 2011-02-10 | The Wistar Institute | Compositions containing jarid1b inhibitors and methods for treating cancer |
| PH12015502575A1 (en) | 2010-03-10 | 2017-04-24 | Incyte Corp | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| US9365553B2 (en) | 2010-05-27 | 2016-06-14 | Aska Pharmaceutical Co., Ltd. | Heterocyclic compound and H1 receptor antagonist |
| WO2012007008A1 (en) | 2010-07-15 | 2012-01-19 | Epitherapeutics Aps | Inhibitors of hdme |
| US20130303545A1 (en) | 2010-09-30 | 2013-11-14 | Tamara Maes | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| GB201112607D0 (en) * | 2011-07-22 | 2011-09-07 | Glaxo Group Ltd | Novel compounds |
| WO2012071469A2 (en) * | 2010-11-23 | 2012-05-31 | Nevada Cancer Institute | Histone demethylase inhibitors and uses thereof for treatment o f cancer |
| PE20141322A1 (es) | 2011-03-25 | 2014-10-05 | Glaxosmithkline Intellectual Property (N 2) Limited | Ciclopropilaminas como inhibidores de desmetilasa 1 especifica de lisina |
| BR112014003382B1 (pt) * | 2011-08-15 | 2022-03-15 | University Of Utah Research Foundation | Análogos de (e)-n-(1-feniletilideno) benzo-hidrazida substituída como inibidores de histona desmetilase e composições farmacêuticas compreendendo-os |
| CN102585150B (zh) | 2012-02-01 | 2013-09-04 | 嘉兴学院 | 织物涂饰用阴离子水性聚氨酯分散体的制备方法 |
| WO2013123411A1 (en) | 2012-02-17 | 2013-08-22 | Board Of Regents, The University Of Texas System | Methods for diagnosing and treating cancer |
| MX2015003959A (es) | 2012-10-02 | 2015-11-16 | Epitherapeutics Aps | Inhibidores de histona demetilasas. |
| ES2834959T3 (es) | 2012-12-06 | 2021-06-21 | Celgene Quanticel Res Inc | Inhibidores de histona desmetilasa |
| US9617242B2 (en) | 2012-12-19 | 2017-04-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| HK1210611A1 (en) | 2012-12-21 | 2016-04-29 | Quanticel Pharmaceuticals Inc | Histone demethylase inhibitors |
| ES2670864T3 (es) | 2013-02-27 | 2018-06-01 | Gilead Sciences, Inc. | Inhibidores de histonas desmetilasas |
| HRP20171609T1 (hr) | 2013-03-15 | 2017-12-15 | Quanticel Pharmaceuticals Inc | Inhibitori histon demetilaze |
| US9505767B2 (en) | 2013-09-05 | 2016-11-29 | Genentech, Inc. | Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors |
| AR099890A1 (es) | 2014-03-31 | 2016-08-24 | Epitherapeutics Aps | Inhibidores de histona demetilasas |
-
2014
- 2014-02-26 ES ES14706607.0T patent/ES2670864T3/es active Active
- 2014-02-26 EP EP16197497.7A patent/EP3170811A1/en not_active Withdrawn
- 2014-02-26 PE PE2015001818A patent/PE20151667A1/es not_active Application Discontinuation
- 2014-02-26 CN CN201480010601.9A patent/CN105263906B/zh active Active
- 2014-02-26 MX MX2015011097A patent/MX2015011097A/es unknown
- 2014-02-26 AU AU2014222756A patent/AU2014222756B2/en active Active
- 2014-02-26 PL PL14706607T patent/PL2961736T3/pl unknown
- 2014-02-26 US US14/381,556 patent/US9650339B2/en active Active
- 2014-02-26 SI SI201430706T patent/SI2961736T1/en unknown
- 2014-02-26 TR TR2018/08599T patent/TR201808599T4/tr unknown
- 2014-02-26 AP AP2015008676A patent/AP2015008676A0/xx unknown
- 2014-02-26 EA EA201591382A patent/EA030451B1/ru not_active IP Right Cessation
- 2014-02-26 KR KR1020157026738A patent/KR102229992B1/ko active Active
- 2014-02-26 JP JP2015558495A patent/JP6514117B2/ja active Active
- 2014-02-26 SG SG11201506717UA patent/SG11201506717UA/en unknown
- 2014-02-26 BR BR112015020650A patent/BR112015020650A2/pt not_active Application Discontinuation
- 2014-02-26 MD MDA20150085A patent/MD20150085A2/ro not_active Application Discontinuation
- 2014-02-26 SG SG10201707027SA patent/SG10201707027SA/en unknown
- 2014-02-26 WO PCT/EP2014/053674 patent/WO2014131777A1/en not_active Ceased
- 2014-02-26 EP EP14706607.0A patent/EP2961736B1/en active Active
- 2014-02-26 CA CA2901022A patent/CA2901022C/en active Active
- 2014-08-28 US US14/472,065 patent/US9221801B2/en active Active
-
2015
- 2015-08-09 IL IL240439A patent/IL240439A0/en unknown
- 2015-08-25 PH PH12015501868A patent/PH12015501868A1/en unknown
- 2015-08-26 CL CL2015002394A patent/CL2015002394A1/es unknown
- 2015-09-24 CR CR20150507A patent/CR20150507A/es unknown
-
2018
- 2018-04-23 JP JP2018082444A patent/JP2018127486A/ja not_active Withdrawn
- 2018-07-13 AU AU2018205204A patent/AU2018205204A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016509047A5 (OSRAM) | ||
| JP2015532295A5 (OSRAM) | ||
| RU2403258C2 (ru) | Тиазолилдигидроиндазолы | |
| RU2018105549A (ru) | Производные бензодиазепина как ингибиторы rsv | |
| JP2013010792A5 (OSRAM) | ||
| RU2350605C2 (ru) | Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ | |
| JP2017526675A5 (OSRAM) | ||
| JP2014507421A5 (OSRAM) | ||
| JP2013512903A5 (OSRAM) | ||
| JP2019524883A5 (OSRAM) | ||
| JP2017511360A5 (OSRAM) | ||
| JP2020505376A5 (OSRAM) | ||
| JP2014503574A5 (OSRAM) | ||
| JP2012512891A5 (OSRAM) | ||
| JP2013532652A5 (OSRAM) | ||
| JP2016510038A5 (OSRAM) | ||
| JP2017519754A5 (OSRAM) | ||
| JP2018522866A5 (OSRAM) | ||
| RU2013148922A (ru) | Три- и тетрациклические пиразоло[3,4-в]пиридины в качестве антинеопластического средства | |
| CA2694270A1 (en) | Substituted aryloxazoles and the use thereof | |
| JP2017523169A5 (OSRAM) | ||
| JP2013506715A5 (OSRAM) | ||
| JP2016518437A5 (OSRAM) | ||
| JP2019522055A5 (OSRAM) | ||
| JP2019505529A5 (OSRAM) |